We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0K3W market cap is 2.93B. The company's latest EPS is USD -3.2032 and P/E is -5.80.
| Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 641.4M | 299.8M | 690.6M | 678.4M | 753.2M |
| Operating Income | -231.7M | -87.8M | -190.5M | -140.6M | -257.4M |
| Net Income | -199.5M | -53.1M | -27.2M | -112M | -263.3M |
| Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.4B | 1.42B | 1.32B | 1.2B | 1.15B |
| Total Liabilities | 486.4M | 537.8M | 352.9M | 312.9M | 363.3M |
| Total Equity | 918.2M | 881M | 967.8M | 885.8M | 783.2M |
| Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 60.7M | -73.7M | 18.2M | -106.3M | -110.9M |
| Investing | 19.3M | 28M | 274.4M | -77.5M | 31.9M |
| Financing | -10M | -2.1M | -150.6M | -8M | 152.9M |
| Market Cap | 2.93B |
| Price to Earnings Ratio | -5.80 |
| Price to Sales Ratio | 2.03 |
| Price to Cash Ratio | 11.57 |
| Price to Book Ratio | 1.95 |
| Dividend Yield | - |
| Shares Outstanding | 82.2M |
| Average Volume (1 week) | 1 |
| Average Volume (1 Month) | 36 |
| 52 Week Change | 0.00% |
| 52 Week High | 35.68 |
| 52 Week Low | 35.68 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Myriad Genetics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.myriad.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
